



# Immugen

Pharmaceuticals, INC.

O.305.666.4093  
F.305.669.4750  
C.305.321.7458  
crt@immugen.com

IFW


Mr. Brian Yong S. Kwon  
U.S. Patent and Trademark Office  
Mail Stop  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA, VA 22313-1450

Dear Mr. Kwon,

I have enclosed an Information Disclosure Statement for the patent on eicosanoid metabolism, Application Number 10/738,457. This should replace the list of articles which I had sent to you on May 22, 2004 which were not included on a form.

Thank you for your cooperation in this matter.

Sincerely,



Craig R. Travis, M.D.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/738,457
				Filing Date	December 16, 2003
				First Named Inventor	Travis, Craig R.
				Art Unit	1614
				Examiner Name	Brian Yong S Kwon
Sheet	1	of	5	Attorney Docket Number	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	LA	AHARONY D, SMITH JB, SILVER MJ. Biochim Biophys Acta. 1982 Oct 8;718(2):193-200.	
	LB	ALANKO J, RIUTTA A, HOLM P, MUCHA I, VAPAATALO H, METSA-KETELA T. Free Radic Biol Med. 1999 Jan;26(1-2):193-201.	
	LC	ALANKO J, RIUTTA A, VAPAATALO H. Prostaglandins Leukot Essent Fatty Acids. 1995 May;52(5):299-301.	
	LD	ALANKO J. Prostaglandins. 1993 Mar;45(3):193-201.	
	LE	ALANKO J, RIUTTA A, MUCHA I, VAPAATALO H, METSA-KETELA T. Free Radic Biol Med. 1993 Jan;14(1):19-25.	
	LF	ANDERSEN NH, EGGERMAN TL, HARKER LA, WILSON CH, DE B. Prostaglandins. 1980 May;19(5):711-35.	
	LG	BARRETT ML, GORDON D, EVANS FJ. Biochem Pharmacol. 1985 Jun 1;34(11):2019-24	
	LH	BARRY OP, KAZANIEZ MG, PRATICO D, FITZGERALD GA. J Biol Chem. 1999 Mar 12;274(11):7545-56.	
	LI	BARRY OP, PRATICO D, SAVANI RC, FITZGERALD GA. J Clin Invest. 1998 Jul 1;102(1):136-44.	
	LJ	BELTON O, BYRNE D, KEARNEY D, LEAHY A, FITZGERALD DJ. Circulation. 2000 Aug 22;102(8):840-5.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:  
**Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/738,457
Sheet	2	of	5	Filing Date	December 16, 2003
				First Named Inventor	Travis, Craig R.
				Art Unit	1614
				Examiner Name	Brian Yong S. Kwon
				Attorney Docket Number	

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	LK	BERTELE V, DE GAETANO G. Eur J Pharmacol. 1982 Dec 3;85(3-4):331-3.			
	LL	BILLS TK, SMITH JB, SILVER MJ. Thromb Haemost. 1978 Oct 31;40(2):219-23. Review.			
	LM	BING RJ, YAMAMOTO T, YAMAMOTO M, KAKAR R, COHEN A. Cardiovasc Res. 1999 Jul;43(1):25-31. Review.			
	LN	BORN GVR. Nature. 1962 Jun 9;194:927-9.			
	LO	BORNHEIM LM, GRILLO MP. Chem Res Toxicol. 1998 Oct;11(10):1209-16.			
	LP	BURSTEIN S, RAZ A. Prostaglandins. 1972 Nov;2(5):369-74.			
	LQ	BURSTEIN S, LEVIN E, VARANELLI C. Biochem Pharmacol. 1973 Nov 15;22(22):2905-10.			
	LR	BURSTEIN S, VARANELLI C, SLADE LT. Biochem Pharmacol. 1975 May 1;24(9):1053-4.			
	LS	BURSTEIN SH, AUDETTE CA, DOYLE SA, HULL K, HUNTER SA, LATHAM V. J Pharmacol Exp Ther. 1989 Nov;251(2):531-5.			
	LT	CAMACHO M, VILA L. Thromb Res. 2000 Jul 15;99(2):155-64.			

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:  
**Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/738,457
(Use as many sheets as necessary)				Filing Date	December 16, 2003
				First Named Inventor	Travis, Craig R.
				Art Unit	1614
				Examiner Name	Brian Yong S Kwon
Sheet	3	of	5	Attorney Docket Number	

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	LU	CAMACHO M, LOPEZ-BELMONTE J, VILA L. Circ Res. 1998 Aug 24;83(4):353-65.	
	LV	EVANS AT, FORMUKONG EA, EVANS FJ. Biochem Pharmacol. 1987 Jun 15;36(12):2035-7.	
	LW	EVANS AT, FORMUKONG E, EVANS FJ. FEBS Lett. 1987 Jan 26;211(2):119-22.	
	LX	EVANS FJ. Planta Med. 1991 Oct;57(7):S60-7. Review.	
	LY	FIDDLER GI, LUMLEY P. Circulation. 1990 Jan;81(1 Suppl):I69-78; discussion I79-80. Review.	
	LZ	FITZGERALD GA, AUSTIN S, EGAN K, CHENG Y, PRATICO D. Ann Med. 2000 Dec;32 Suppl 1:21-6. Review.	
	MA	FITZGERALD GA, OATES JA. Clin Pharmacol Ther. 1984 May;35(5):633-40.	
	MB	FITZGERALD GA, BRASH AR, OATES JA, PEDERSEN AK. J Clin Invest. 1983 Oct;72(4):1336-43.	
	MC	FITZGERALD GA, PEDERSEN AK, PATRONO C. Circulation. 1983 Jun;67(6):1174-7.	
	MD	FORMUKONG EA, EVANS AT, EVANS FJ. J Pharm Pharmacol. 1989 Oct;41(10):705-9.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>				<b>Complete if Known</b>	
				<b>Application Number</b>	10/738,457
				<b>Filing Date</b>	December 16, 2003
				<b>First Named Inventor</b>	Travis, Craig R.
				<b>Art Unit</b>	1614
				<b>Examiner Name</b>	Brian Yong S. Kwon
Sheet	4	of	5	Attorney Docket Number	

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	ME	KULMACZ RJ, LANDS WE. J Biol Chem. 1985 Oct 15;260(23):12572-8.	
	MF	LIBBY P. Circulation. 2001 Jul 17;104(3):365-72. Review.	
	MG	LIBBY P. Circulation. 1995 Jun 1;91(11):2844-50. Review.	
	MH	LINDER BL, GOODMAN DS. Blood. 1982 Aug;60(2):436-45.	
	MI	McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, et al Proc Natl Acad Sci USA. 1999 Jan 5;96(1):272-7. Erratum in: Proc Natl Acad Sci USA 1999 May 11;96(10):58	
	MJ	NATHAN I, AGAM G, MECHOULAM R, DILANSKY A, LIVNE AA. Can J Physiol Pharmacol. 1992 Oct;70(10):1305-8.	
	MK	NATHAN I, YAROM A, DVILANSKY A, LANDER N, LIVNE A. Biochem Pharmacol. 1982 Feb 1;31(3):439-41..	
	ML	REILLY M, FITZGERALD GA. Eur Heart J. 1993 Dec;14 Suppl K:88-93. Review.	
	MM	ROSS R. Am Heart J. 1999 Nov;138(5 Pt 2):S419-20. Review.	
	MN	SEKIYA F, TAKAGI J, SASAKI K, KAWAJIRI K, KOBAYASHI Y, SATO F, SAITO Y. Biochim Biophys Acta. 1990 May 1;1044(1):165-8.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

5

of

5

		Complete if Known	
Application Number		10/738,457	
Filing Date		December 16, 2003	
First Named Inventor		Travis, Craig R.	
Art Unit		1614	
Examiner Name		Brian Yong S. Kwon	
Attorney Docket Number			

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	MO	SILVER MJ, SMITH JB, INGERMAN C, KOCSIS JJ. Prostaglandins. 1973 Dec;4(6):863-75.	
	MP	SPRONCK HJ, LUTEIJN JM, SALEMINK CA, NUGTEREN DH. Biochem Pharmacol. 1978 Feb 15;27(4):607-8.	
	MQ	TANSIK RL, NAMM DH, WHITE HL. Prostaglandins. 1978 Mar;15(3):399-408.	
	MR	THOMPSON D, ELING T. Mol Pharmacol. 1989 Nov;36(5):809-17.	
	MS	TOPPER JN, CAI J, FALB D, GIMBRONE MA JR. Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10417-22.	
	MT	ULLRICH V, ZOU MH, BACHSCHMID M. Biochim Biophys Acta. 2001 May 31;1532(1-2):1-14. Review. .	
	MU	VANE JR, BAKHLE YS, BOTTING RM. Annu Rev Pharmacol Toxicol. 1998;38:97-120. Review.	
	MV	WADE ML, VOELKEL NF, FITZPATRICK FA. Arch Biochem Biophys. 1995 Aug 20;321(2):453-8.	
	MW	WHITE HL, TANSIK RL. Prostaglandins Med. 1980 Jun;4(6):409-17.	

Examiner Signature	Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.